Apoptosis News and Research RSS Feed - Apoptosis News and Research

Apoptosis is programmed cell death, the body's normal method of disposing of damaged, unwanted, or unneeded cells.
Study provides platform for detailed study of nerve injury and repair during Wallerian degeneration

Study provides platform for detailed study of nerve injury and repair during Wallerian degeneration

Wallerian degeneration is a subject of major interest in neuroscience. A large number of genes are differentially regulated during the distinct stages of Wallerian degeneration: transcription factor activation, immune response, myelin cell differentiation and dedifferentiation. [More]
Researchers identify RNA that modulates action of important gene in process of programmed cell death

Researchers identify RNA that modulates action of important gene in process of programmed cell death

Researchers from the University of S-o Paulo (USP) have identified an RNA known as INXS that, although containing no instructions for the production of a protein, modulates the action of an important gene in the process of apoptosis, or programmed cell death. [More]
Researchers discover new function of body's most important tumor-suppressing protein

Researchers discover new function of body's most important tumor-suppressing protein

Researchers at Cold Spring Harbor Laboratory (CSHL) have discovered a new function of the body's most important tumor-suppressing protein. Called p53, this protein has been called "the guardian of the genome." [More]
Study provides potential drug targets for transient cerebral ischemia-reperfusion injury

Study provides potential drug targets for transient cerebral ischemia-reperfusion injury

Mitochondria play an important role in neuronal apoptosis caused by cerebral ischemia. Researchers at the Affiliated Hospital of Qingdao University, China discovered transient ischemia led to cell apoptosis in the hippocampus and changes in memory and cognition of aged rats. [More]
Kinex receives FDA approval to begin Phase I study of KX2-391 Ointment for actinic keratosis

Kinex receives FDA approval to begin Phase I study of KX2-391 Ointment for actinic keratosis

Kinex Pharmaceuticals announced the receipt of an allowance by the US FDA for the Company's KX2-391 Ointment for the commencement of a Phase I clinical study in actinic keratosis. This is the Company's third IND to be allowed by the US FDA in the past 12 months. [More]
AMSBIO-Trevigen prize winner announced

AMSBIO-Trevigen prize winner announced

AMSBIO, regular sponsor of the annual Beatson International Cancer Conference announces that the winner of the AMSBIO-Trevigen prize for the best poster was Katarzyna Grzes - a PhD researcher specialising in Cell Signaling and Immunology at the University of Dundee (Scotland, UK).
Miss Grzes was named as winner of the Poster Prize for the best presented and most interesting poster for her work entitled 'Metabolic regulation in PTEN null T lymphoma / leukemia'. [More]
Capsazepine shows dramatic tumor shrinkage without damaging surrounding tissues

Capsazepine shows dramatic tumor shrinkage without damaging surrounding tissues

Mouse models of human oral cancer treated with an agent called capsazepine showed dramatic tumor shrinkage without damage to surrounding tissues, researchers from the School of Dentistry and School of Medicine at The University of Texas Health Science Center at San Antonio found. [More]
Co-targeting strategies suggested for EGFR-TKI resistance in NSCLC

Co-targeting strategies suggested for EGFR-TKI resistance in NSCLC

Researchers have identified additional resistance mechanisms that could be targeted to improve the efficacy of irreversible epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small-cell lung cancer harbouring both EGFR and T790M mutations. [More]
Autoimmune diseases share certain pathogenic mechanisms with cancer

Autoimmune diseases share certain pathogenic mechanisms with cancer

Autoimmune disorders may share certain pathogenic mechanisms with cancer, according to a new report by George Washington University researcher Linda Kusner, Ph.D., published in PLOS ONE on July 22. [More]
CIP2A pathway involved in erlotinib response

CIP2A pathway involved in erlotinib response

Researchers have identified a novel mechanism, involving the cancerous inhibitor of protein phosphatase 2A pathway, which mediates the anti-tumour effects of erlotinib in non-small-cell lung cancer cells without epidermal growth factor receptor mutations. [More]
Acute glaucoma is largely an inflammatory disease, say researchers

Acute glaucoma is largely an inflammatory disease, say researchers

Researchers at the University of California, San Diego School of Medicine and Sun Yat-sen University in China have shown that acute glaucoma in mice is largely an inflammatory disease and that high pressure in the eye causes vision loss by setting in motion an inflammatory response similar to that evoked by bacterial infections. [More]
Can-Fite's CF102 drug gets approval in Israel for patient with hepatocellular carcinoma

Can-Fite's CF102 drug gets approval in Israel for patient with hepatocellular carcinoma

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that the Israeli Ministry of Health has approved the use of its drug CF102 for a patient with hepatocellular carcinoma, the most common form of liver cancer, under the country's Compassionate Use Program. [More]
University of Louisville researchers take a step forward in battle against lung cancer

University of Louisville researchers take a step forward in battle against lung cancer

Researchers at the University of Louisville have uncovered a cadre of small molecules that tell certain proteins to kill lung cancer cells. The team, led by Chi Li, Ph.D., assistant professor of medicine, published its finding in the April 2014 issue of Molecular and Cellular Biology. [More]
Adeno-associated virus type 2 kills triple-negative breast cancer cells in mice

Adeno-associated virus type 2 kills triple-negative breast cancer cells in mice

A virus not known to cause disease kills triple-negative breast cancer cells and killed tumors grown from these cells in mice, according to Penn State College of Medicine researchers. Understanding how the virus kills cancer may lead to new treatments for breast cancer. [More]
Alcoholic liver disease: an interview with Dr Vinood Patel, University of Westminster

Alcoholic liver disease: an interview with Dr Vinood Patel, University of Westminster

Alcoholic liver disease (ALD) is one of the leading causes of death worldwide and also in the UK. As its name indicates this disease arises due to consuming excessive amounts of alcohol (80 g/day) over an extended period, normally 10-20 years. [More]
Researchers demonstrate potential of retinoic acid in preventing type 2 diabetes complications

Researchers demonstrate potential of retinoic acid in preventing type 2 diabetes complications

At a time when obesity, type 2 diabetes, and their complications are a veritable epidemic worldwide, researchers at the University of Montreal and CHUM Research Centre (CRCHUM) recently demonstrated the potential of retinoic acid (RA), a derivative of Vitamin A, in treating obesity and type 2 diabetes and preventing their cardiovascular complications. [More]
Mechanisms of recurrent bacteria AOM in children under scrutiny

Mechanisms of recurrent bacteria AOM in children under scrutiny

The immune response in young children with bacterial acute otitis media differs between individuals who are prone to such infection and those who are not, US researchers have shown. [More]
Study: The brain controls cellular process that leads to glaucoma

Study: The brain controls cellular process that leads to glaucoma

Findings from a new study published in Translational Vision Science & Technology show the brain, not the eye, controls the cellular process that leads to glaucoma. The results may help develop treatments for one of the world's leading causes of irreversible blindness, as well as contribute to the development of future therapies for preserving brain function in other age-related disorders like Alzheimer's. [More]
FDA approves Can-Fite's study protocol for CF102 Phase II clinical trial for advanced liver cancer

FDA approves Can-Fite's study protocol for CF102 Phase II clinical trial for advanced liver cancer

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that the U.S. FDA has agreed with the Company's study protocol for its Phase II clinical trial of CF102 for the treatment of advanced liver cancer. [More]
Fibrogen reports FG-3019 Phase 2 study results for treatment of pancreatic cancer

Fibrogen reports FG-3019 Phase 2 study results for treatment of pancreatic cancer

FibroGen, Inc. today announced results from a Phase 2 open-label study of FG-3019, an investigational anti-fibrotic antibody, in combination with gemcitabine and erlotinib for the treatment of patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC). [More]